Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Exenatide on disease progression in early Parkinson's disease
2019-000732-26Phase 2Active
- Sponsor
- Stockholms Läns Sjukvårdsområde
- Start
- May 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Exenatide (BYDUREON) with Placebo (2 arms). Primary endpoint: FDG-PET network analysis. Started May 2019; status: active.
02
Drugs
exenatide extended-release
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2019-000732-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000732-26.